{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:37:02Z","timestamp":1784907422050,"version":"3.55.0"},"posted":{"date-parts":[[2024,6,15]]},"group-title":"Radiology and Imaging","reference-count":34,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,10,7]]},"abstract":"<jats:p>Introduction Differences in amyloid positron emission tomography (PET) radiotracer pharmacokinetics and binding properties lead to discrepancies in amyloid-\u03b2 uptake estimates. Harmonization of tracer-specific biases is crucial for optimal performance of downstream tasks. Here, we investigated the efficacy of ComBat, a data-driven harmonization model, for reducing tracer-specific biases in regional amyloid PET measurements from [18F]-florbetapir (FBP) and [11C]-Pittsburgh Compound-B (PiB). Methods One-hundred-thirteen head-to-head FBP-PiB scan pairs, scanned from the same subject within ninety days, were selected from the Open Access Series of Imaging Studies 3 (OASIS-3) dataset. The Centiloid scale, ComBat with no covariates, ComBat with biological covariates, and GAM-ComBat with biological covariates were used to harmonize both global and regional amyloid standardized uptake value ratios (SUVR). Variants of ComBat, including longitudinal ComBat and PEACE, were also tested. Intraclass correlation coefficient (ICC) and mean absolute error (MAE) were computed to measure the absolute agreement between tracers. Additionally, longitudinal amyloid SUVRs from an anti-amyloid drug trial were simulated using linear mixed effects modeling. Differences in rates-of-change between simulated treatment and placebo groups were tested, and change in statistical power\/Type-I error after harmonization was quantified. Results In the head-to-head tracer comparison, ComBat with no covariates was the best at increasing ICC and decreasing MAE of both global summary and regional amyloid PET SUVRs between scan pairs of the same group of subjects. In the clinical trial simulation, harmonization with both Centiloid and ComBat increased statistical power of detecting true rate-of-change differences between groups and decreased false discovery rate in the absence of a treatment effect. The greatest benefit of harmonization was observed when groups exhibited differing FBP-to-PiB proportions. Conclusion ComBat outperformed the Centiloid scale in harmonizing both global and regional amyloid estimates. Additionally, ComBat improved the detection of rate-of-change differences between clinical trial groups. Our findings suggest that ComBat is a viable alternative to Centiloid for harmonizing regional amyloid PET analyses.<\/jats:p>","DOI":"10.1101\/2024.06.14.24308952","type":"posted-content","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T15:15:13Z","timestamp":1718464513000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of ComBat harmonization for reducing across-tracer differences in regional amyloid PET analyses"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2558-4132","authenticated-orcid":false,"given":"Braden","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8671-8424","authenticated-orcid":false,"given":"Tom","family":"Earnest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-0734","authenticated-orcid":false,"given":"Sayantan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deydeep","family":"Kothapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-0552","authenticated-orcid":false,"given":"Tammie","family":"Benzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-2955","authenticated-orcid":false,"given":"Brian","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0795-8820","authenticated-orcid":false,"given":"Aristeidis","family":"Sotiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2024062006151091000_2024.06.14.24308952v1.1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263195"},{"key":"2024062006151091000_2024.06.14.24308952v1.2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","year":"2021","journal-title":"Alz Res Therapy"},{"key":"2024062006151091000_2024.06.14.24308952v1.3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial","volume":"79","year":"2022","journal-title":"JAMA Neurology"},{"key":"2024062006151091000_2024.06.14.24308952v1.4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.neurobiolaging.2017.06.027","article-title":"Identifying incipient dementia individuals using machine learning and amyloid imaging","volume":"59","year":"2017","journal-title":"Neurobiology of Aging"},{"key":"2024062006151091000_2024.06.14.24308952v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2018.02.017"},{"key":"2024062006151091000_2024.06.14.24308952v1.6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neurobiolaging.2021.06.014","article-title":"Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer\u2019s disease","volume":"106","year":"2021","journal-title":"Neurobiology of Aging"},{"key":"2024062006151091000_2024.06.14.24308952v1.7","first-page":"e12037","article-title":"Topographical distribution of A\u03b2 predicts progression to dementia in A\u03b2 positive mild cognitive impairment","volume":"12","year":"2020","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"2024062006151091000_2024.06.14.24308952v1.8","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/alz.12491","article-title":"Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer\u2019s disease dementia","volume":"17","year":"2021","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2024062006151091000_2024.06.14.24308952v1.9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20009"},{"key":"2024062006151091000_2024.06.14.24308952v1.10","first-page":"180","article-title":"Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies","volume":"11","year":"2019","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"2024062006151091000_2024.06.14.24308952v1.11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302548"},{"key":"2024062006151091000_2024.06.14.24308952v1.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.109009"},{"key":"2024062006151091000_2024.06.14.24308952v1.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2088-x"},{"key":"2024062006151091000_2024.06.14.24308952v1.14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00259-015-3156-9","article-title":"Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024062006151091000_2024.06.14.24308952v1.15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.nicl.2015.10.007","article-title":"Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer\u2019s subjects","volume":"9","year":"2015","journal-title":"NeuroImage: Clinical"},{"key":"2024062006151091000_2024.06.14.24308952v1.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2753-3"},{"key":"2024062006151091000_2024.06.14.24308952v1.17","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1007\/s00259-023-06209-0","article-title":"Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2\/3 clinical trial of anti-amyloid-\u03b2 monoclonal antibodies in dominantly inherited Alzheimer\u2019s disease","volume":"50","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024062006151091000_2024.06.14.24308952v1.18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET","volume":"11","year":"2015","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2024062006151091000_2024.06.14.24308952v1.19","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/alz.12317","article-title":"AMYQ: An index to standardize quantitative amyloid load across PET tracers","volume":"17","year":"2021","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2024062006151091000_2024.06.14.24308952v1.20","doi-asserted-by":"crossref","first-page":"117593","DOI":"10.1016\/j.neuroimage.2020.117593","article-title":"Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies","volume":"226","year":"2021","journal-title":"NeuroImage"},{"key":"2024062006151091000_2024.06.14.24308952v1.21","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/alz.13677","article-title":"Harmonizing florbetapir and PiB PET measurements of cortical A\u03b2 plaque burden using multiple regions-of-interest and machine learning techniques: An alternative to the Centiloid approach","volume":"20","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2024062006151091000_2024.06.14.24308952v1.22","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1007\/s00259-020-05131-z","article-title":"Improved amyloid burden quantification with nonspecific estimates using deep learning","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024062006151091000_2024.06.14.24308952v1.23","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxj037"},{"key":"2024062006151091000_2024.06.14.24308952v1.24","doi-asserted-by":"crossref","first-page":"100136","DOI":"10.1016\/j.ynirp.2022.100136","article-title":"Validation of cross-sectional and longitudinal ComBat harmonization methods for magnetic resonance imaging data on a travelling subject cohort","volume":"2","year":"2022","journal-title":"Neuroimage: Reports"},{"key":"2024062006151091000_2024.06.14.24308952v1.25","doi-asserted-by":"crossref","first-page":"119509","DOI":"10.1016\/j.neuroimage.2022.119509","article-title":"A comparison of methods to harmonize cortical thickness measurements across scanners and sites","volume":"261","year":"2022","journal-title":"NeuroImage"},{"key":"2024062006151091000_2024.06.14.24308952v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2019.116450"},{"key":"2024062006151091000_2024.06.14.24308952v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEUROIMAGE.2017.11.024"},{"key":"2024062006151091000_2024.06.14.24308952v1.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263102"},{"key":"2024062006151091000_2024.06.14.24308952v1.29","first-page":"e12436","article-title":"Probabilistic estimation for across-batch compatibility enhancement for amyloid PET","volume":"15","year":"2023","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"2024062006151091000_2024.06.14.24308952v1.30","doi-asserted-by":"crossref","unstructured":"LaMontagne PJ , Benzinger TLS , Morris JC , Keefe S , Hornbeck R , Xiong C , et al. OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease. medRxiv. 2019;2019.12.13.19014902.","DOI":"10.1101\/2019.12.13.19014902"},{"key":"2024062006151091000_2024.06.14.24308952v1.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073377"},{"key":"2024062006151091000_2024.06.14.24308952v1.32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.nicl.2018.04.022","article-title":"Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies","volume":"19","year":"2018","journal-title":"NeuroImage: Clinical"},{"key":"2024062006151091000_2024.06.14.24308952v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2014.11.058"},{"key":"2024062006151091000_2024.06.14.24308952v1.34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.neuroimage.2018.11.019","article-title":"Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers","volume":"186","year":"2019","journal-title":"NeuroImage"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.06.14.24308952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:03:24Z","timestamp":1768507404000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.06.14.24308952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1101\/2024.06.14.24308952","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1002\/hbm.70068","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,6,15]]},"subtype":"preprint"}}